Head-to-head · Cost-Efficiency Index
Next Vial vs Wisp
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Next Vial
Shoppers who want a named pharmacy partner and verified LegitScript status without a membership fee.
Visit Next VialWisp
Cost-first shoppers who want branded injectables plus a sublingual semaglutide alternative.
Visit WispThe verdict
Next Vial and Wisp tie on the Cost-Efficiency Index at 63/100, so neither wins outright on the numbers. For most shoppers we'd start with Next Vial (ranked #198, a hair above #202) — Shoppers who want a named pharmacy partner and verified LegitScript status without a membership fee. But Wisp is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Next Vial.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Next Vial | Wisp |
|---|---|---|
| Cost-Efficiency Index | 63/100 | 63/100 |
| Semaglutide / mo | $249/mo (all doses, compounded) | $225/mo (compounded oral) |
| Tirzepatide / mo | $249/mo (all doses, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $2,988 | $2,700 |
| Tirzepatide / yr (modeled) | $2,988 | — |
| Coverage | 49 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #198 | #202 |
Next Vial
63/100Where the value is
- Names its compounding pharmacy partner explicitly (Manifest Pharmacy, Greer, SC)
- Genuine LegitScript verification link found in the footer
- Explicit 44-state coverage list published in the FAQ
The tradeoffs
- Starting price is blended/generic ($249.97/mo) and not broken out by drug or dose tier anywhere public
- No individual medical director named
Wisp
63/100Where the value is
- Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
- LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
- Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary
The tradeoffs
- The $99/mo tirzepatide figure is a consultation-and-care subscription, not the medication: Zepbound is filled at a pharmacy of your choice at its own cost, which Wisp does not publish
- The compounded semaglutide option is sublingual drops, which Wisp itself describes as less effective than injection
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.